Trials · Topics · Other/Supportive Care
Other/Supportive Care clinical trials
7 Other/Supportive Care trials (Medical Oncology) summarized for clinical practice and board review, newest first within each disease. Each summary covers design, results, toxicity and what changed in practice.
Jump to: Pharmacology · Immunotherapy Toxicity Management · Adrenocortical Carcinoma - advanced
Pharmacology (4)
- CIVIC POD trial J Clin Oncol 2026A completely dexamethasone-free antiemetic regimen built on olanzapine, palonosetron and fosaprepitant was noninferior to standard dexamethasone-containing triple...
- NEPA + olanzapine CINV trial J Clin Oncol 2026NEPA plus olanzapine with a single 6 mg day-1 dose of dexamethasone, or no dexamethasone, was non-inferior to standard 4-day dexamethasone for CINV prevention in HEC...
- Proton Pump Inhibitor Use in Recurrent Glioblastoma Eur J Cancer 2026No evidence that PA-PPI use compromises outcome in recurrent glioblastoma. Prior first-line MGMT status and steroid requirements are primary confounders. Disconnect...
- Romiplostim for CIT Pediatric Blood & Cancer 2026Romiplostim may decrease chemotherapy dose reductions and delays in pediatric solid tumors with CIT, potentially allowing maintenance of dose intensity. The observed...
Immunotherapy Toxicity Management (2)
- Hematological ICI Toxicity Pharmacovigilance Study Cancer Immunol Immunother 2026Hematologic and thrombotic AEs associated with ICI therapy show notable reporting frequencies, with combination regimens demonstrating stronger signals. Early onset...
- Hematological Immune-Related Adverse Events from ICIs: Management Review Cancer Treat Rev 2026Prompt recognition and management of hematologic irAEs is critical to minimize morbidity, preserve ICI efficacy, and avoid premature discontinuation. Increased...
Adrenocortical Carcinoma - advanced (1)
- FIRM-ACT NEJM 2012EDP+mitotane significantly improved ORR and PFS over streptozotocin+mitotane in advanced ACC, establishing EDP+M as the reference first-line regimen. The primary OS...